Fox Run Management L.L.C. Invests $252,000 in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Fox Run Management L.L.C. invested approximately $252,000 in Kiniksa Pharmaceuticals International, acquiring 11,352 shares during the first quarter.
• Several hedge funds, including Russell Investments Group Ltd. and Nuveen LLC, also significantly increased their stakes in Kiniksa during the same period, indicating growing institutional interest in the company.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share, surpassing analyst expectations and contributing to a positive outlook with a consensus price target of $41.17 among analysts.

Fox Run Management L.L.C. bought a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,352 shares of the company's stock, valued at approximately $252,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. GAMMA Investing LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after purchasing an additional 568 shares in the last quarter. US Bancorp DE acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at $33,000. Asset Management One Co. Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at $42,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at $61,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 17,000 shares of the firm's stock in a transaction on Monday, August 4th. The shares were sold at an average price of $32.35, for a total transaction of $549,950.00. Following the completion of the sale, the chief accounting officer directly owned 33,041 shares of the company's stock, valued at approximately $1,068,876.35. This trade represents a 33.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Ragosa sold 18,889 shares of the stock in a transaction on Monday, August 4th. The shares were sold at an average price of $32.89, for a total transaction of $621,259.21. Following the transaction, the chief financial officer owned 27,009 shares in the company, valued at $888,326.01. This trade represents a 41.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 655,532 shares of company stock worth $20,622,436. 53.48% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals International Stock Up 1.6%

Shares of Kiniksa Pharmaceuticals International stock traded up $0.53 during trading hours on Tuesday, hitting $33.57. The company's stock had a trading volume of 584,624 shares, compared to its average volume of 672,465. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $34.55. The business has a fifty day moving average of $29.98 and a 200 day moving average of $25.72. The company has a market capitalization of $2.49 billion, a PE ratio of 839.46 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Wells Fargo & Company raised their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Finally, Jefferies Financial Group raised their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.